Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
41,451,901
-
Share change
-
+1,538,499
-
Total reported value
-
$95,375,596
-
Price per share
-
$2.30
-
Number of holders
-
79
-
Value change
-
-$5,753,342
-
Number of buys
-
33
-
Number of sells
-
36
Institutional Holders of AEGLEA BIOTHERAPEUTICS INC - COM (AGLE) as of Q1 2022
As of 31 Mar 2022,
AEGLEA BIOTHERAPEUTICS INC - COM (AGLE) was held by
79 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
41,451,901 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, Nantahala Capital Management, LLC, ORBIMED ADVISORS LLC, BlackRock Inc., Bain Capital Life Sciences Investors, LLC, PICTET ASSET MANAGEMENT SA, VANGUARD GROUP INC, Rock Springs Capital Management LP, and Aisling Capital Management LP.
This page lists
79
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.